There is an increasing focus on the potential contributory mechanistic role of the gut microbiota in the metabolic effects of glucoregulatory and weight loss promoting drugs, including glucagon-like peptide-1 (GLP-1) receptor agonists, which have become well-established therapies in type 2 diabetes and obesity 16,17
In addition, do not use if you have: multiple endocrine neoplasia type 2 (tumors in your glands) a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) diabetic ketoacidosis (call your doctor for treatment)
Transmembrane signal transduction by peptide hormones via family B G protein-coupled receptors
Emdin CA, Khera AV, Kathiresan S
No in-person visits, no insurance required
Beaumont JEJ, Barbeau LMO, Ju J, Savelkouls KG, Bouwman FG, Zonneveld MI, et al